Join our daily newsletter At The Bell to receive exclusive market insights
- Patrys (PAB) sees a range of PAT-DX1 studies published in peer-reviewed journal ImmunoHorizons supporting its use in treating certain cancers and inflammatory diseases
- Recent studies have shown neutrophil extracellular traps (NETs) play a crucial role in the spread of cancer and regulating inflammation
- PAT-DX1 is known to hinder the DNA damage repair process in cell nuclei, a mechanism which contributes to the formulation of NETs
- The new publication found the drug has the ability to restrict the production of NETS, thereby, providing a treatment solution for cancer and certain inflammatory diseases
- Shares are trading flat at two cents each at 11:39 am AEST
Patrys (PAB) has had a range of PAT-DX1 studies published in peer-reviewed journal ImmunoHorizons supporting its use in treating certain cancers and inflammatory diseases.
Recent studies have shown neutrophil extracellular traps (NETs) play a crucial role in the spread of cancer and regulating inflammation.
PAT-DX1 is known to hinder the DNA damage repair process in cell nuclei, a mechanism which contributes to the formulation of NETs.
The new publication found the drug has the ability to restrict the production of NETS, thereby, providing a treatment solution for cancer and certain inflammatory diseases.
CEO and Managing Director Dr James Campbell was pleased with the findings.
“This is an unexpected and important discovery for Patrys, offering mechanistic rationale to the previously described ability of PAT-DX1 to reduce cancer spread by metastasis, and opening the door to broader uses of deoxymabs in non-cancer indications, particularly chronic inflammatory conditions that are driven by NET formation,” he said.
“The discovery has been protected by patent application, and opens new areas for business development to Patrys.”
Shares were trading flat at two cents each at 11:39 am AEST.
